NEW YORK, April 9, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on ABT, ABMD, ALGN, and AVGR which can be accessed for free by signing up to www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com monitors Abbott Laboratories (NYSE: ABT),
Abbott Park, Illinois headquartered Abbott Laboratories' shares recorded a trading volume of 7.45 million shares last Friday, which was above their three months average volume of 7.19 million shares. The stock finished the trading session 3.83% lower at $57.57. The Company's shares have gained 31.44% over the past year. The stock is trading above its 200-day moving average by 4.64%. Furthermore, shares of Abbott Labs, which discovers, develops, manufactures, and sells health care products worldwide, a Relative Strength Index (RSI) of 38.79.
On March 21st, 2018, Abbott Labs announced that it will report its Q1 2018 financial results on April 18th, 2018, before the market opens. A live webcast of the earnings conference call will follow at 9:00 a.m. ET. The webcast will be accessible on the Company's Investor Relations website. Get the full research report on ABT for free by clicking below at: www.wallstequities.com/registration/?symbol=ABT
On Friday, Danvers, Massachusetts headquartered ABIOMED Inc.'s stock ended the session 2.02% lower at $286.22. A total volume of 334,799 shares was traded. The Company's shares have gained 0.29% in the last month, 43.65% over the previous three months, and 131.94% over the past year. The stock is trading 6.79% above its 50-day moving average and 46.13% above its 200-day moving average. Moreover, shares of ABIOMED, which engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart, have an RSI of 54.31.
On March 30th, 2018, ABIOMED announced that Todd A. Trapp will be appointed as Vice President and CFO, effective April 09th, 2018. Mr. Trapp, 47, joins the Company from Watts Water Technologies, Inc., where he served as CFO since 2015.
On April 04th, 2018, research firm Goldman initiated a 'Buy' rating on the Company's stock, with a target price of $332 per share. The free technical report on ABMD can be accessed at: www.wallstequities.com/registration/?symbol=ABMD
San Jose, California headquartered Align Technology Inc.'s stock ended the day 3.96% lower at $245.23 with a total trading volume of 909,541 shares. The Company's shares have gained 5.11% over the previous three months and 113.61% over the past year. The stock is trading 13.79% above its 200-day moving average. Additionally, shares of Align Technology, which designs, manufactures, and markets a system of clear aligner therapy, intraoral scanners, and computer-aided design and computer-aided manufacturing digital services, have an RSI of 44.44.
On April 02nd, 2018, Align Technology announced that it will release its Q1 2018 financial results on April 25th, 2018, at 4:00 p.m. ET. Following the press release, the Company will host a conference call at 4:30 p.m. ET to discuss its financial results. A live audio webcast will be accessible on the Company's investor website. Sign up for free on Wall St. Equities and claim the latest report on ALGN at: www.wallstequities.com/registration/?symbol=ALGN
Shares in Redwood City, California headquartered Avinger Inc. recorded a trading volume of 225,895 shares. The stock ended Friday's session 0.85% lower at $1.17. The Company's shares are trading below their 50-day moving average by 55.14%. Furthermore, shares of Avinger, which designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease in the US and Europe, have an RSI of 31.40.
On March 09th, 2018, research firm Ladenburg Thalmann initiated a 'Buy' rating on the Company's stock.
On March 29th, 2018, Avinger announced that Arne Schwindt, M.D., a vascular surgeon at St. Franziskus Hospital in Münster, Germany, successfully treated the first three patients with the extended nosecone version of the next generation Pantheris Lumivascular atherectomy system (A400EX). This product is a line extension of the existing next generation platform, with a longer nosecone that enhances the plaque removal capacity of the device, in addition to the feature improvements of the next generation of devices. See the free research coverage on AVGR at: www.wallstequities.com/registration/?symbol=AVGR
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/quotidian-technical-highlights-on-selected-medical-equipment-stocks----abbott-laboratories-abiomed-align-technology-and-avinger-300626184.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Blount's disease is a developmental disorder in which the shinbone is affected, resulting in ...
Acanthosis nigricans is a skin condition in which discoloration and hyperpigmentation of the skin ...
Gastrointestinal Bleeding refers to hemorrhage that occurs from one or more portions of the ...View All